HLAVNÍ TÉMA Kardiovaskulární rizika systémové léčby glukokortikoidy | 369 / Vnitř Lék. 2024;70(6):366-369 / VNITŘNÍ LÉKAŘSTVÍ www.casopisvnitrnilekarstvi.cz 10. Souverein PC, Berard A, Van Staa TP et al. Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study. Heart. 2004;90(8):859-65. 11. Ajeganova S, Svensson B, Hafström I et al. Low-dose prednisolone treatment of early rheumatoid arthritis and late cardiovascular outcome and survival: 10-year follow-up of a 2-year randomised trial. BMJ Open. 2014;4(4):e004259. 12. Pujades-Rodriguez M, Morgan AW, Cubbon RM et al. Dose-dependent oral glucocorticoid cardiovascular risks in people with immune-mediated inflammatory diseases: A population-based cohort study. PLoS Med. 2020;17(12):e1003432. 13. Aviña-Zubieta JA, Abrahamowicz M, De Vera MA et al. Immediate and past cumulative effects of oral glucocorticoids on the risk of acute myocardial infarction in rheumatoid arthritis: a population-based study. Rheumatology (Oxford). 2013;52(1):68-75. 14. So H, Lam TO, Meng H et al. Time and dose-dependent effect of systemic glucocorticoids on major adverse cardiovascular event in patients with rheumatoid arthritis: a population-based study. Ann Rheum Dis. 2023;82(11):1387-93. 15. van der Hooft CS, Heeringa J, Brusselle GG et al. Corticosteroids and the risk of atrial fibrillation. Arch Intern Med. 2006;166(9):1016-20. 16. Christiansen CF, Christensen S, Mehnert F et al. Glucocorticoid use and risk of atrial fibrillation or flutter: a population-based, case-control study. Arch Intern Med. 2009;169(18):1677-83. 17. Akikusa JD, Feldman BM, Gross GJ et al. Sinus bradycardia after intravenous pulse methylprednisolone. Pediatrics. 2007;119(3):e778-82. 18. White KP, Driscoll MS, Rothe MJ et al. Severe adverse cardiovascular effects of pulse steroid therapy: is continuous cardiac monitoring necessary? J Am Acad Dermatol. 1994;30(5 Pt 1):768-73. 19. Majoor CJ, Kamphuisen PW, Zwinderman AH et al. Risk of deep vein thrombosis and pulmonary embolism in asthma. Eur Respir J. 2013;42(3):655-61. 20. Waljee AK, Rogers MA, Lin P et al. Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study. BMJ. 2017;357:j1415. 21. Lieber BA, Han J, Appelboom G et al. Association of Steroid Use with Deep Venous Thrombosis and Pulmonary Embolism in Neurosurgical Patients: A National Database Analysis. World Neurosurg. 2016;89:126-32. 22. Petri M, Perez-Gutthann S, Spence D et al. Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am J Med. 1992;93(5):513-9. 23. Drosos GC, Vedder D, Houben E et al. EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome. Ann Rheum Dis. 2022;81(6):768-79. 24. Kršek M. [Systemic glucocorticoids treatment: practical view]. Vnitr Lek. 2015;61(10):905-13. ODBORNÝ GARANT MUDr. Michal Krčma, Ph.D. Průběžně aktualizovaný program a registrace: www.diabetologieplzen.cz POŘADATEL A KONTAKT SOLEN, s. r. o., v odborné spolupráci s I. interní klinikou FN Plzeň Markéta Slezáková slezakova@solen.cz +420 721 135 146 MÍSTO KONÁNÍ Parkhotel Congress Center Plzeň U Borského parku 31, Plzeň diabetologie pro praxi 12. 2. 2025 PARKHOTEL PLZEŇ 2.kongres PLÁNOVANÉ TEMATICKÉ BLOKY DIABETES MELLITUS A TĚHOTENSTVÍ Garanti: MUDr. Daniela Čechurová, as. MUDr. Vladimír Korečko DIABETES MELLITUS A CHIRURGIE Garanti: prof. MUDr. Jiří Moláček, Ph.D., MUDr. Viktor Zlocha DIABETES MELLITUS A POSUDKOVÁ ČINNOST Garanti: MUDr. Bc. Petra Sládková, Ph.D., MUDr. Jan Brož, Ph.D. KAZUISTIKY Z PRAXE REGISTRAČNÍ POPLATEK při registraci do 31. 12. 2024: 700 Kč při registraci do 6. 2. 2025: 900 Kč při registraci od 7. 2. 2025: 1 100 Kč 40% sleva pro lékaře do 35 let 20% slevapro předplatitele časopisů vydavatelství Solen na rok 2025 www.visitplzen.eu
RkJQdWJsaXNoZXIy NDA4Mjc=